The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug data with comprehensive drug target information.
The latest release of DrugBank (version 5.1.5, released 2020-01-03) contains 13,488 drug entries including 2,641 approved small molecule drugs, 1,364 approved biologics (proteins, peptides, vaccines, and allergenics), 130 nutraceuticals and over 6,347 experimental (discovery-phase) drugs. Additionally, 5,189 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.
- MorphineAn opioid agonist used for the relief of moderate to severe acute and chronic pain.
- OxycodoneAn opioid used in the management of moderate to severe pain.
- AcetaminophenAn analgesic drug used alone or in combination with opioids for pain management, and as an antipyretic agent.
- CodeineAn opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated.
- SalbutamolA beta-2 adrenergic receptor agonist used to treat asthma, bronchitis, COPD, as well as prevent exercise induced bronchospasms.
- Acetylsalicylic acidA salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events.
Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.
A Year in Review: DrugBank's 2019 Highlights
DrugBank accepted into Creative Destruction Lab - West 2019/20 Cohort
Using DrugBank Data in AI Drug Discovery: A Case Study
DrugBank Fall 2019 Feature Release
Cannabinoids in Epilepsy: A New Era of Treatments
From Discovery to Resistance to Progress
Ketamine: the key to treatment resistant depression?
Tideglusib: From Alzheimer's to Caries Lesion Natural Repair
CFTR Modulators Helping CF Patients Catch Their Breath
New Antivirals Provide Hope for Eradication of Hepatitis C – If You Can Afford It
DrugBank is offered to the public as a freely available resource.
Use and re-distribution of the data, in whole or in part, for commercial purposes (including internal use) requires a license. We ask that users who download significant portions of the database cite the DrugBank paper in any resulting publications.